La bourse est fermée

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Cours en temps réel. Devise en USD
Ajouter à la liste dynamique
245,17-1,36 (-0,55 %)
À la clôture : 04:00PM EST
245,76 +0,59 (+0,24 %)
Échanges après Bourse : 07:59PM EST

Amgen Inc.

One Amgen Center Drive
Thousand Oaks, CA 91320-1799
United States
805 447 1000
https://www.amgen.com

Secteur(s)Healthcare
Secteur d’activitéDrug Manufacturers—General
Employés à temps plein

Dirigeants clés

NomTitrePayerExercéAnnée de naissance
Mr. Robert A. BradwayChairman, CEO & Pres5,81M13,3M1963
Mr. Peter H. GriffithExec. VP & CFO2,66MS.O.1959
Mr. Esteban SantosExec. VP of Operations2,61MS.O.1968
Dr. David M. Reese M.D.Exec. VP of R&D2,79M419,8k1963
Mr. Murdo GordonExec. VP of Global Commercial Operations2,82MS.O.1967
Ms. Linda H. LouieVP of Fin. & Chief Accounting OfficerS.O.S.O.S.O.
Mr. Mike ZahigianSr. VP & Chief Information OfficerS.O.S.O.S.O.
Mr. Arvind SoodVP of Investor RelationsS.O.S.O.S.O.
Mr. Jonathan P. GrahamExec. VP, Gen. Counsel & Sec.S.O.S.O.1961
Ms. Nancy A. GrygielSr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance OfficerS.O.S.O.1968
Les montants ont été établis en date du 31 décembre 2021 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Amgen Inc. en date du 1 février 2023 est 1. Les scores principaux sont Audit : 2; Société : 8; Droits des actionnaires : 1; Compensation : 1.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.